Jasper Therapeutics, Inc. (JSPR)
After hours:
| Previous close | 0.7512 |
| Open | 0.7500 |
| Bid | 0.7002 x 1100 |
| Ask | 0.8000 x 40000 |
| Day's range | 0.6905 - 0.7966 |
| 52-week range | 0.3860 - 3.8000 |
| Volume | |
| Avg. volume | 303,759 |
| Market cap | 86.424M |
| Beta (5Y monthly) | 1.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9500 |
| Earnings date | 08 Nov 2023 - 13 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireJasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium
All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recoveryBriquilimab was well tolerated without any complicationsStudy expansion to Phase 2a is ongoing REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermedi
- GlobeNewswire
Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced that it will participate at the Cantor Fitzgerald 2023 Global Healthcare Conference
GlobeNewswireJasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeStrengthened the Board of Directors and Management Team with Multiple Appointments REDWOOD CITY, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndro
